Sökning: id:"swepub:oai:lup.lub.lu.se:1f42eab4-63e4-4762-af8f-aceb3594fce8" >
The 5-lipoxygenase-...
The 5-lipoxygenase-activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma
-
Kent, S. E. (författare)
-
Boyce, M. (författare)
-
- Diamant, Zuzana (författare)
- Lund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine
-
visa fler...
-
Singh, D. (författare)
-
O'Connor, B. J. (författare)
-
Saggu, P. S. (författare)
-
Norris, V. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2013-01-18
- 2013
- Engelska.
-
Ingår i: Clinical and Experimental Allergy. - : Wiley. - 1365-2222 .- 0954-7894. ; 43:2, s. 177-186
- Relaterad länk:
-
http://www.ncbi.nlm.... (free)
-
visa fler...
-
http://dx.doi.org/10...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background GSK2190915, a potent 5-lipoxygenase-activating protein inhibitor, prevents the synthesis of leukotrienes and 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE). Objective To assess the effect of GSK2190915 on the allergen-induced asthmatic responses. Methods Nineteen eligible male subjects with mild asthma were enrolled in and completed this four-centre, double-blind, two-way crossover study (ClinicalTrials.gov NCT00748306). Subjects took GSK2190915 100 mg and placebo orally once daily for 5 days in randomized order. On Day 1 and 4 they had a methacholine challenge, on Day 3 they had an inhaled allergen challenge, and on Days 4 and 6 they had sputum induction. Results GSK2190915 attenuated the early (02 h) and late (410 h) asthmatic responses to inhaled allergen compared with placebo. There was a statistically significant attenuation of the early asthmatic response (EAR) by GSK2190915; treatment difference of GSK2190915 vs. placebo for the minimum FEV1 EAR was 0.408 L (0.205, 0.611). There was a statistically significant attenuation of the late asthmatic response (LAR) by GSK2190915; the treatment difference of GSK2190915 vs. placebo for the minimum FEV1 LAR was 0.229 L (0.041, 0.417). There was a statistically significant attenuation of allergen-induced sputum eosinophil count on Day 4 following GSK2190915: mean treatment difference (95% CI) between GSK2190915 and placebo was -9.95% (-18.15%, -1.77%). Compared with placebo, GSK2190915 100 mg reduced median sputum LTB4 by > 90% on Days 4 and 6. There was no effect on methacholine PC20 post allergen. GSK2190915 was generally well tolerated. Conclusion and Clinical Relevance GSK2190915 shows potential as a treatment for patients with asthma.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)
Nyckelord
- 5-lipoxygenase-activating protein inhibitor
- AM803
- bronchial allergen
- challenge
- GSK2190915
- leukotriene
- sputum eosinophils
Publikations- och innehållstyp
- art (ämneskategori)
- ref (ämneskategori)
Hitta via bibliotek
Till lärosätets databas